Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 295

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial

Open access
Chappell, Lucy C, Bell, Jennifer L, Smith, Anne, Linsell, Louise, Juszczak, Edmund, Dixon, Peter H, Chambers, Jenny, Hunter, Rachael, Dorling, Jon, Williamson, Catherine, Thornton, Jim G, Ahmed, Irshad, Arya, Rita, Beckett, Virginia, Bhide, Amarnath, Brown, Heather, Bugg, George, Cameron, Helen, Deole, Nishigandh, Dey, Madhuchanda, Dwyer, James, Fahel, Leila, Gada, Ruta, Girling, Joanna, Haestier, Anna, Hughes, Sean, Indusekhar, Radha, Jones, Bryony, Khan, Rahila, Kirkpatrick, Alison, Knox, Ellen, Lincoln, Karen, MacDougall, Malcolm, Majoko, Franz, McIntyre, Karen, Noori, Muna, Oakley, Wendy, Preston, Jane, Ranka, Poornima, Rashid, Mumtaz, Salloum, Marwan, Samyraju, Manjula, Schram, Catharina, Sen, Seema, Stone, Sophia, Tan, Bee·2019·The Lancet

Abstract

BACKGROUND: Intrahepatic cholestasis of pregnancy, characterised by maternal pruritus and increased serum bile acid concentrations, is associated with increased rates of stillbirth, preterm birth, and neonatal unit admission. Ursodeoxycholic acid is widely used as a treatment without an adequate evidence base. We aimed to evaluate whether ursodeoxycholic acid reduces adverse perinatal outcomes in women with intrahepatic cholestasis of pregnancy. METHODS: We did a double-blind, multicentre, randomised placebo-controlled trial at 33 hospital maternity units in England and Wales. We recruited women with intrahepatic cholestasis of pregnancy, who were aged 18 years or older and with a gestational age between 20 weeks and 40 weeks and 6 days, with a singleton or twin pregnancy and no known lethal fetal anomaly. Participants were randomly assigned 1:1 to ursodeoxycholic acid or placebo, given as two oral tablets a day at an equivalent dose of 500 mg twice a day. The dose could be increased or decreased at the clinician's discretion, to a maximum of four tablets and a minimum of one tablet a day. We recommended that treatment should be continued from enrolment until the infant's birth. The primary outcome was a composite of perinatal death (in-utero fetal death after randomisation or known neonatal death up to 7 days after birth), preterm delivery (<37 weeks' gestation), or neonatal unit admission for at least 4 h (from birth until hospital discharge). Each infant was counted once within this composite. All analyses were done according to the intention-to-treat principle. The trial was prospectively registered with the ISRCTN registry, number 91918806. FINDINGS: Between Dec 23, 2015, and Aug 7, 2018, 605 women were enrolled and randomly allocated to receive ursodeoxycholic acid (n=305) or placebo (n=300). The primary outcome analysis included 304 women and 322 infants in the ursodeoxycholic acid group, and 300 women and 318 infants in the placebo group (consent to use data was withdrawn for 1 woman and 2 infants). The primary composite outcome occurred in 74 (23%) of 322 infants in the ursodeoxycholic acid group and 85 (27%) of 318 infants in the placebo group (adjusted risk ratio 0·85 [95% CI 0·62-1·15]). Two serious adverse events were reported in the ursodeoxycholic acid group and six serious adverse events were reported in the placebo group; no serious adverse events were regarded as being related to treatment. INTERPRETATION: Treatment with ursodeoxycholic acid does not reduce adverse perinatal outcomes in women with intrahepatic cholestasis of pregnancy. Therefore, its routine use for this condition should be reconsidered. FUNDING: National Institute for Health Research Efficacy and Mechanism Evaluation Programme.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(19)31270-x

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 295

Metadata

Authors
Chappell, L. C., Bell, J. L., Smith, A., Linsell, L., Juszczak, E., Dixon, P. H., Chambers, J., Hunter, R., Dorling, J., Williamson, C., Thornton, J. G., Ahmed, I., Arya, R., Beckett, V., Bhide, A., Brown, H., Bugg, G., Cameron, H., Deole, N., Dey, M., Dwyer, J., Fahel, L., Gada, R., Girling, J., Haestier, A., Hughes, S., Indusekhar, R., Jones, B., Khan, R., Kirkpatrick, A., Knox, E., Lincoln, K., MacDougall, M., Majoko, F., McIntyre, K., Noori, M., Oakley, W., Preston, J., Ranka, P., Rashid, M., Salloum, M., Samyraju, M., Schram, C., Sen, S., Stone, S., & Tan, B.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-09
Volume
394
Issue
10201
Pages
849-860
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2966395542
Cited by
295
References
24
FWCI
35.95
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)31270-x
The paper
Chappell, L. C., Bell, J. L., Smith, A., Linsell, L., Juszczak, E., Dixon, P. H., Chambers, J., Hunter, R., Dorling, J., Williamson, C., Thornton, J. G., Ahmed, I., Arya, R., Beckett, V., Bhide, A., Brown, H., Bugg, G., Cameron, H., Deole, N., . . . Tan, B. (2019). Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)31270-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.